Items where Author is "Mohammadi, Shiva"

Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | No Grouping
Jump to: Article
Number of items: 7.

Article

Mohammadi, Shiva and Kavusi Pour, Soudabe and Jalili, Sajad and Barazesh, Mahdi (2024) Designing of a Novel Candidate Multi-epitope Vaccine to boost Immune Responses against SARS-COV-2 using Immunoinformatics and Machine Learning based Approach. Letters in Drug Design and Discovery, 21. pp. 356-375.

Mohammadi, Shiva and Dalaei Moghadam, Maryam and Nasiriasl, Maryam and Akhzari, Morteza and Barazesh, Mahdi (2024) Insights into the Therapeutic and Pharmacological Properties of Resveratrol as a Nutraceutical Antioxidant Polyphenol in Health Promotion and Disease Prevention. Current reviews in clinical and experimental pharmacology..

Nazarnezhad, Mirza Ali and Barazesh, Mahdi and Mohammadi, Shiva (2022) The Computational Analysis of Single Nucleotide Associated with MicroRNA Affecting Hepatitis B Infection. Microrna.

Nazarnezhad, Mirza Ali and Barazesh, Mahdi and Kavousipour, Soudabeh and Mohammadi, Shiva (2022) Computational Analysis of Single Nucleotide Polymorphisms Associated with MicroRNA Affecting Hepatitis B Infection. Microrna.

Barazesh, Mahdi and Mohammadi, Shiva and Bahrami, Yadollah and Mokarram, Pooneh and Morowvat, Mohammad Hossein and Saidijam, Massoud (2021) CRISPR/Cas9 Technology as a Modern Genetic Manipulation Tool for Recapitulating of Neurodegenerative Disorders in Large Animal Models. Current Gene Therapy.

Mohammadi, Shiva and Kavousipour, Soudabeh and Eftekhar, Ebrahim and Jalili, Sajad and Arabizadeh, Elham (2021) In silico approach to predict the SARS-CoV-2 derived candidate MiRNAs as a potential antiviral therapy. Current Drug Therapy.

Mohammadi, Shiva and Fallahi, Shirzad and Shakarami, Amir and Kavousipour, Soudabeh and Barazesh, Mahdi (2021) In silico evaluation of various signal peptides to improve secretion of humulin protein in E. coli host. Current Proteomics.

This list was generated on Sun Apr 14 02:08:41 2024 IRDT.